Q2 FY27 revenue up 47%; contract manufacturing target INR1,000 crore

Management guided margin improvementOrder pipeline disclosedMulti-year targets disclosedInvestor Communications View source PDF Explain this filing

AARTIPHARM · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-0.3%Reaction day

₹929.95

prior close

₹945.00

announcement price

After-mkt

timing

Nifty Microcap 250market+1.1%-1.5% vs market

Pharmaceuticals peers, median of 171sector+0.5%-0.9% vs sector

On the reaction day the stock moved 1.5 pts less than Nifty Microcap 250 and 0.9 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-1.5

10m

-1.8

15m

-1.6

30m

-1.0

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-0.3+1.1-1.5+0.5-0.9

Next day

+0.0pendingpending+0.4-0.4

—————

15d

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 171Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Standalone Q2 FY27 revenue rose 47% year on year to INR613 crore, EBITDA rose 84% to INR136 crore and profit after tax reached INR66 crore. EBITDA margin improved to 22.2% from 17.7%. Contract manufacturing was 13% of revenue and had 59 active projects, including 39 in commercial stages. Management expects 40% to 50% growth this year and targets INR1,000 crore of segment revenue within about three years.

Likely market impact

Growth and capacity ramp-ups support the outlook, but higher depreciation, working capital needs and more debt for capex could pressure cash flow.